Global Parkinson’s Disease Drugs Market Report and Forecast 2024-2032

Global Parkinson’s Disease Drugs Market Outlook

The global Parkinson s disease drugs industry is expected to grow at a CAGR of about 7.9% in the forecast period of 2024-2032 to reach a value of around USD 13.26 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Europe Leading the Parkinson’s Disease Drugs Market

The availability of proper health facilities, pharmaceutical options, diagnostic labs, and skilled personnel like neurologists can improve the detection of Parkinson’s disease. Europe, followed by North America, are at the forefront of this market because of the presence of the above facilities. This is further bolstered by government funding for research and growing health awareness is expected to further improve the market for these drugs. In Asia Pacific, the growth rate for Parkinson’s disease drugs is expected to be high in the forecast period 2024-2032 because of the growing ageing population in Japan and China. Furthermore, with improving healthcare networks in Asia Pacific, the market is further expected to rise in the coming years.

Parkinson’s Disease Drugs: Market Segmentation

Parkinson’s disease is a neurogenerative disease which affects motor capabilities. It generally occurs in senior citizens and the symptoms include shaking of limbs, stiffness, and walking and speech difficulty. This is a result of nerve damage because of which the dopamine levels in the brain can drop, leading to this disease. Since there are inadequate resources for the diagnosis of this disease, the disease often goes undetected till a later stage.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Parkinson’s disease drugs market can be segmented by drug class into:

• MAO-B Inhibitors
• Levodopa
• COMT Inhibitors
• Dopamine Agonists
• Anticholinergics
• Others

It may be differentiated by route of administration into:

• Oral 
• Injection
• Transdermal

It may be divided on the basis of distribution channels into:

• Hospital Pharmacies
• Retail Pharmacies
• Online
• Others

The market may be differentiated on the basis of end-use as:

• Hospitals
• Clinics
• Others

The regional markets for Parkinson’s disease drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Generic Drugs Bolstering the Market Growth

For Parkinson’s disease, the first response is usually medication. As generic drugs gain a stronger foothold, especially in developing countries, companies can expect to expand into wider markets. With a rise in skilled professionals like neurologists and lab technicians, the detection rate of the disease will also increase, in turn increasing the market for drugs. Stronger drug pipelines of pharmaceutical companies will positively affect the market too. Over time, a rise in the sales of drugs is expected because of increasing presence of diagnostic labs and chemist shops. Growing health awareness and improving healthcare facilities, especially in developing countries is expected to positively impact the growth of the market.

Key Industry Players in the Global Parkinson’s Disease Drugs Market

The report gives a detailed analysis of the following key players in the global Parkinson’s disease drugs industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.
• Medtronic plc
• GlaxoSmithKline plc.
• AbbVie Inc.
• Novartis AG
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report